Glycopeptide antibiotics, vancomycin and teicoplanin, are active against most gram-positive bacteria and are increasingly used in the treatment of infections due to staphylococci, streptococci, and enterococci. Pediococcus spp., Leuconostoc spp., and certain species of Lactobacillus are intrinsicalJ. resistant to these antibiotics (5, 6) . Acquired resistance to glycopeptides is still uncommon, despite the use of vancomycin in human therapy for over three decades. However, several re'cent reports emphasize the emergence and spread of resistance to these drugs in Staphylococcus spp. and Enterococcus spp.
In staphylococci, vancomycin resistance was first described in a strain of Staphylococcus haemolyticus recovered after treatment with this antibiotic (20) . Coagulasenegative staphylococci, mainly S. haemolyticus strains, resistant to teicoplanin ard susceptible to vancomycin have also been reported (2, 9, 28) .
In enterococci, acquired resistance to glycopeptides is inducible by these antibiotics and two phenotypes can be distinguished: (i) low-level resistance to vancomycin only (13, 19, 27) and (ii) high-level resistance to vancomycin and teicoplanin (15, 16, 18, 21) . In both phenotypes, induction of resistance is associated with inducible synthesis of a protein of ca. 40 kilodaltons (18, 21, 27) .
We previously established that in four clinical isolates of Enterococcus faecium, the determinants for high-level resistance to glycopeptides were plasmid borne (15, 16) . Three of the plasmids were self-transferable to other enterococci (16) . In the remaining strain, E. faecium BM4147, the genetic information for glycopeptide resistance was carried by the nonconjugative plasmid pIP816 (4, 15) . The resistance determinant of pIP816 was cloned into Escherichia coli (4) (3 strains) , and blood cultures (1 strain). E. faecalis strains were isolated from blood cultures (one strain) and pus (one strain). The origins of two E. faecalis and two E. faecium strains were not specified. Enterococci were identified by Gram staining; absence of catalase; inability to produce gas; presence of Lancefield antigen group D; and growth on 40% bile, in 6.5% sodium chloride, in 0.1% methylene blue, and at pH 9.6. Species identification was based on the tests for reduction of potassium tellurite and for acid production from 50 carbohydrates in API 50 CH galleries (API System, la Balme-les-Grottes, France). Four enterococcal isolates resistant to low levels of vancomycin and detected in the United States in 1988 were studied: E. faecalis V583 (19) , isolated from blood cultures, and three strains of Enterococcus gallinarum (13) isolated from pus (two strains) and blood cultures (one strain). The 23 staphylococcal strains (15 Staphylococcus epidermidis and 8 S. haemolyticus) resistant to teicoplanin and susceptible to vancomycin were isolated in 1987 at Henri Mondor fHospital (Creteil, France) and were identified by the method of Kloos and Schleifer (14) ; the strains appeared unrelated since they had different antibiotic resistance phenotypes. E. faecalis JH2-2 (11); E. faecium BM4107, BM4147-1, BM4165-1, and BM4178-1 (15, 16); Staphylococcus aureus 80CR5 (8); and S. epidermidis BM4625 from our laboratory collection were used as susceptible control strains.
Intrinsically resistant Leuconostoc dextranicum (1 strain), Leuconostoc mesenteroides (1 strain), Leuconostoc paramesenteroides (1 strain), Leuconostoc lactis (1 strain), Leuconostoc pseudomesenteroides (1 strain), Leuconostoc citreum (1 strain), Lactobacillus confusus (2 strains), and Pediococcus spp. (11 strains) were from the collections of R. R. Facklam and of our laboratory. Amycolatopsis orientalis ATCC 19795, which produces vancomycin, was provided by N. Allen. DNA of Actinoplanes teichomyceticus ATCC 31211, which produces teicoplanin, was provided by M. Denaro.
Media. Brain heart infusion broth and agar (Difco Laboratories, Detroit, Mich.) were used. Susceptibility tests were performed on Mueller-Hinton agar (Diagnostics Pasteur, Marnes-la-Coquette, France) supplemented with 5% horse blood. All incubations were at 37°C.
Determination of in vitro susceptibility to antibiotics. The diffusion test with disks containing 30 jig of vancomycin or teicoplanin (Diagnostics Pasteur) was used. Disks containing 500 pug of streptomycin or gentamicin and 1,000 jig of kanamycin were used to screen enterococci for high-level resistance to aminoglycosides. P-Lactamase production was assessed with Cefinase disks (bioMerieux, Marcy l'Etoile, France). The method of Steers et al. (22) with 104 CFU per spot was used to determine the MICs of antibiotics. Transfer of antibiotic resistance traits. Matings on filters were performed as previously described (23) . E. faecium BM4107 (16) and E. faecalis JH2-2 (11), resistant to fusidic acid and rifampin, were used as recipients in mating experiments with enterococci, lactobacilli, leuconostocs, and pediococci. Transconjugants from mating between enterococci were selected on plates containing 50 ,g of rifampin per ml and 20 ,g of fusidic acid per ml plus each of the following: erythromycin, 10 ,ug/ml; gentamicin, 100 ,ug/ml; kanamycin or streptomycin, 400 ,uglml; tetracycline, 8 ,ug/ml; and vancornycin, 10 ,ug/ml. The antibiotic resistance of five transconjugants from every selective plate was determined. In matings with lactobacilli, leuconostocs, and pediococci as donors, only transfer of vancomycin resistance (10 ,g/ml) was selected for. Antibiotic concentrations for selection of transfer of teicoplanin resistance from coagulase-negative staphylococci to S. aureus 80CR5 and S. epidermidis BM4625 were as follows: rifampin, 50 ,g/ml; fusidic acid, 20 ,ug/ml; and teicoplanin, 8 ,ug/ml. Transfer frequencies were expressed relative to the number of donor CFU after the mating period.
Preparation of DNA. Cells from 1. purified by alkaline lysis as described previously (7, 24) . DNA-DNA hybridization. The DNA probe consisted of the 290-base-pair BamHI-RsaI fragment internal to the vanA gene. The DNA fragment cloned in bacteriophage M13mpl8 was hybridized with the 15-base-pair distal primer and labeled by DNA synthesis in the presence of dGTP, dATP, dTTP, [a-32P]dCTP, and DNA polymerase (Klenow fragment) (10) . Hybridization in stringent conditions was at 65°C in a solution containing 0.1% sodium dodecyl sulfate, 0.7% nonfat dry milk, 6x SSC (lx SSC is 0.15 M NaCl plus 0.015 M sodium citrate, pH 7.0) overnight (12) . Washings were at 65°C in 2x SSC-0.1% sodium dodecyl sulfate. Hybridization in moderately stringent conditions was at 60°C overnight, and washings were at 45°C.
Enzymes and reagents. Lysostaphin and lysozyme were from Sigma Chemical Co. (St. Louis, Mo.). RNase A (bovine pancreas) and proteinase K were from Calbiochem Corp. (San Diego, Calif.), and [a-32P]dCTP-triethylammonium salt (specific activity, 400 Ci/mmol) was obtained from the Radiochemical Centre (Amersham Corp.). Ramoplanin and teicoplanin were provided by Gruppo Lepetit (Milan, Italy); vancomycin and daptomycin were from Eli Lilly & Co. (Indianapolis, Ind.).
RESULTS
Glycopeptide resistance phenotypes. The clinical isolates could be assigned to three groups (designated 1, 2, and 3) of glycopeptide resistance phenotypes (Table 1) . Group 1 consisted of 27 strains of E. faecium and 4 strains of E. faecalis, originating from France, Spain, and the United Kingdom, that were highly resistant to glycopeptides. The MICs of vancomycin and teicoplanin against these strains were greater than or equal to 64 and 16 ,ug/ml, respectively (greater than 256 and 64 jig/ml, respectively, for 24 of the 31 strains). When tested by the disk-agar diffusion technique, the cultures grew at the point of contact of disks containing 30 jig of vancomycin or teicoplanin. The E. faecium strains were all resistant to penicillin G (MICs 2 16 p.g/ml) but did not produce a ,B-lactamase. Glycopeptide resistance was associated with resistance to macrolides-lincosamides-streptogramin B-type antibiotics (27 strains), tetracycline (28 strains), streptomycin and kanamycin (18 strains), and chloramphenicol (8 strains). Eight combinations of resistance characters could be distinguished among the 31 isolates.
The second group was composed of E. faecalis V583 (19) and of three strains of E. gallinarum (13) , isolated in the Analysis of DNA by hybridization. Homology was detected, by dot blot hybridization, between the probe specific for vanA and DNA of the 31 strains of enterococci and of the 16 transconjugants highly resistant to glycopeptides (Table  1) . We did not observe homology with the other strains, including the cured derivatives, even under moderately stringent hybridization conditions. DISCUSSION Reports on emergence of glycopeptide resistance in grampositive cocci are recent, in spite of more than three decades of therapeutical use of vancomycin (26) . The long delay between the initial use of glycopeptides and emergence of resistance is rather surprising when compared with the situation in other antibiotic families. Acquired resistance to glycopeptides was observed in both staphylococci and enterococci. Review of the literature indicates that different resistance phenotypes can be distinguished in these bacterial genera. However, comparative analyses of the resistance phenotypes are limited to a few clinical isolates, and the resistance determinants were not compared. We have gathered 35 glycopeptide-resistant enterococci previously described or prospectively collected in 10 hospitals in France, Spain, the United Kingdom, and the United States. The enterococcal isolates can be considered representative of glycopeptide-resistant strains from various geographical areas that have emerged since 1986. We also studied strains of coagulase-negative staphylococci from our hospital that are resistant to teicoplanin, and we included gram-positive bacteria that are naturally resistant to glycopeptides from other laboratory collections. The strains with acquired resistance could be assigned to three groups, each corresponding to a glycopeptide resistance phenotype (Table 1) .
The 31 E. faecium and E. faecalis strains in group 1 and the corresponding transconjugants were resistant to high levels of vancomycin and teicoplanin. All the strains grew at the point of contact of the vancomycin and teicoplanin disks and hybridized with the vanA probe. These results indicate that a single class of vanA-related genes is responsible for high-level resistance in enterococci. The wide range of glycopeptide MICs against these strains indicated phenotypic heterogeneity for vanA resistance determinants.
The vanA gene was detected in two species of enterococci, and within a species, the strains could be distinguished on the basis of their biotypes (data not shown) and their resistance phenotypes. We previously established that in four E. faecium strains, the glycopeptide resistance determinants were borne by one mobilizable and three selftransferable plasmids (15, 16 274, 1989 ) is consistent with this notion. However, these results do not exclude the possibility that heterologous genes encode functionally related proteins. Studies on the mechanism of glycopeptide resistance suggest that these proteins may have similar functions (1).
Twenty-three staphylococcal strains in group 3 were resistant to low levels of teicoplanin but susceptible to vancomycin. The probe did not hybridize with DNA of these isolates, indicating that the teicoplanin resistance determinants in Staphylococcus spp. are distinct from vanA. To our knowledge, glycopeptide resistance determinants from staphylococci and enterococci had not yet been compared.
The plasmid location of vanA and the lack of hybridization between the probe and the chromosome of glycopeptidesusceptible strains indicated an exogenous origin for this gene in Enterococcus spp. In several families of antibiotics, similarities have been detected between the resistance mechanisms in human pathogens and the mechanisms by which antibiotic-producing bacteria avoid self-destruction. It has been proposed that this analogy might indicate that the resistance genes found in human pathogens originated in antibiotic producers (3, 25) . Since then, accumulation of data on the amino acid sequences of resistance proteins from both groups of organisms has neither dismissed nor confirmed this hypothesis. The structural genes for the proteins were found to be related, but horizontal gene transfer could not be inferred because of substantial sequence divergences. We did not detect homology between the vanA probe and genomic DNA of Amycolatopsis orientalis ATCC 19795, which produces vancomycin, nor with genomic DNA of Actinoplanes teichomyceticus ATCC 31211, which produces teicoplanin. This observation indicates that emergence of high-level glycopeptide resistance in enterococci is not due to recent acquisition of a gene from one of these antibiotic producers. However, a lack of relationship between resistance determinants or a difference in resistance mechanisms cannot be inferred from negative hybridizations data. Similarly, vanA apparently does not originate in, Laetpbacillus, Pediococcus, or Leuconostoc spp., which are intrinsically resistant to glycopeptide antibiotics; antibodies against the protein associated with high-level resistance in enterococci also did not cross-react with members of these bacterial genera (17) .
